Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1994-06-30
1998-06-02
Kight, John
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
424 111, 424 165, 530300, 530329, 530330, A61K 5100, A61M 3614
Patent
active
057595151
ABSTRACT:
High affinity linked, branched or linear repeat peptides containing two or more biological-function domains and at least one medically useful metal ion-binding domain are labeled with medically useful metal ions for use in a variety of diseases and pathologic conditions, including diagnosis and treatment of diseases. Such peptides include high affinity chemotactic peptides containing a biological-function domain which includes at least two linked N-formyl-MLF (SEQ. ID NO. 2) sequences and high affinity repeat and branched peptides containing two or more YIGSR (SEQ. ID NO. 1) sequences.
REFERENCES:
patent: 4424200 (1984-01-01), Crockford et al.
patent: 4427646 (1984-01-01), Olexa et al.
patent: 4479930 (1984-10-01), Hnatowich
patent: 4668503 (1987-05-01), Hnatowich
patent: 4732864 (1988-03-01), Tolman
patent: 4904642 (1990-02-01), Coy et al.
patent: 4986979 (1991-01-01), Morgan, Jr. et al.
patent: 5039662 (1991-08-01), Schasteen
patent: 5061641 (1991-10-01), Shochat et al.
patent: 5078985 (1992-01-01), Rhodes
patent: 5091514 (1992-02-01), Fritzberg et al.
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5102990 (1992-04-01), Rhodes
patent: 5128119 (1992-07-01), Griffiths
patent: 5162505 (1992-11-01), Dean et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5225180 (1993-07-01), Dean et al.
patent: 5225530 (1993-07-01), Bernardi et al.
patent: 5229490 (1993-07-01), Tam
patent: 5236903 (1993-08-01), Saiki et al.
patent: 5371184 (1994-12-01), Rajagopalan et al.
patent: 5443816 (1995-08-01), Zamora et al.
patent: 5508020 (1996-04-01), Dean et al.
Bard, D.R., et al., "BisMSH-DTPA: A Potential Imaging Agent for Malignant Melanoma," Ann NY Acad Sci. 680, pp. 451-453 (1993).
Bard, D.R., et al., "A Chelating Derivative of .alpha.-Melanocyte Stimulating Hormone as a Potential Imaging Agent for Malignant Melanoma," Br J Cancer, vol. 62 pp. 919-922 (1990).
Cox, P.H., et al., "Technetium Labelled Somatostatin A Potential Agent for In Vivo Tumour Localization," 7th Int'l Sympos on Radiopharm., p. 16 (1991) Abstract.
Fischman, A.J., et al., "A Ticket to Ride: Peptide Radiopharmaceuticals," J Nucl Med, vol. 34, No. 12, pp. 2253-2263 (1993).
Hynes, R.O., "Inegrins: Versatility, Modulation, and Signaling in Cell Adhesion," Cell, vol. 69, pp. 11-25 (1992).
Ill, C.R., et al., "Adhesion of Platelets to Laminin in the Absence of Activation," J Cell Bio, vol. 99, pp. 2140-2145, (1984).
Khaw, B.A., et al., "Technetium-99m Labeling of Antibodies to Cardiac Myosin Fab and to Human Fibrinogen," J Nucl Med, vol. 23, No. 11, pp. 1011-1019 (1982).
Knight, L.C., et al., "Thrombus Imaging with TC-99m Synthetic Peptides Reactive with Activated Platelets," J Nucl Med, vol. 31, No. 5, No. 209 Abstract (May 1990).
Kondo, M., et al., "Studies of Dimeric fMLF with High Chemotactic Activities," Peptides: Chemistry and Biology, JA Smith and JE Rivier, eds., ESCOM, Leiden, pp. 425-426 (1992).
Kraus, J, et al., "Cyclic Tetrameric Clusters of Chemotactic Peptides as Superactive Activators of Lysozyme Release from Human Meutrophils," Bilchem and Biophy Res Comm, vol. 124, No. 3, pp. 939-944 (1984).
Sonnenberg, A., et al., "Isolation of .differential.6.beta.1 Integrins from Platelets and Adherent Cells by Chromatography on Mouse Laminin Fragment E8 and Human Laminin Pepsin Fragment," Exp Cell Res, vol. 197, pp. 234-244 (1991).
Tandon, N.N., et al., "Interaction of Human Platelets with Laminin and Identification of 67 kDa Laminin Receptor on Platelets," Riochem J, vol. 2724, pp. 535-542 (1991).
Swanson, D., et al., "In-111 Laminin Peptide Fragments for Malignant Tumor Detection," J Nucl Med, 34, 231P Abstract (1993).
Wraight, E.P., et al., "The Use of Chelating Derivative of Alpha Melanocyte Stimulating Hormone for the Clinical Imaging of Malignant Melanoma," Brit J Rad, vol. 65, pp. 112-118 (1992).
Yamada, K.M., "Adhesive Recognition Sequences," J Biol Chem, vol. 266, No. 20, pp. 12809-12812 (1992).
Pimm, M.V., et al., "In labelling of a branched polypeptide drug carrier with a poly(L-lysine) backbone," Int'l J. Pharm., vol. 79 (1992), pp. 77-80.
Nakai et al. "A Synthetic Antagonist to Laminin Inhibits the Formation of Osteolytic Metastases by Human Melanoma Cells in Nude Mice". Cancer Research, vol. 52, pp. 5395-5399, Oct. 1, 1992.
Saiki et al. "Antimetastatic effects of synthetic polypeptides containing repeated structures of the cell adhesive Arg-Gly-Asp (RGD) and Tyr-Ile-Gly-Ser-Arg, (YIGSR) sequences". British Journal of Cancer, vol. 60, pp. 722-728, (1989).
Saiki et al "The inhibition of murine lung metastatis by synthetic poly sequence of cell adhesion molecules". British Journal of Cancer, vol. 59, pp. 194-197, (1989).
Freer Richard J.
Rhodes Buck A.
Sharma Shubh D.
Zamora Paul O.
Jones Dameron
Kight John
RhoMed Incorporated
LandOfFree
Polyvalent peptide pharmaceutical applications does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyvalent peptide pharmaceutical applications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyvalent peptide pharmaceutical applications will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456444